AMENDMENT NO. 1 TO LICENSE AGREEMENT

Exhibit 10.18

AMENDMENT NO. 1 TO

LICENSE AGREEMENT

Amendment No. 1 to License (this " Amendment ") made as of August 2, 2006, by and between Acuity Pharmaceuticals, Inc. , a Delaware corporation, with its principal offices at 3701 Market Street, Philadelphia, PA, 19104 ( "Acuity ") and Pathogenics, Inc. , a Delaware Corporation with its principal offices at 99 Derby Street, Suite 200, Hingham, MA 02043 (" Pathogenics ").

BACKGROUND

WHEREAS, Acuity and Pathogenics entered into a License Agreement (the " License Agreement ") on April 13, 2006;

WHEREAS, Section 3.2(d)(i) of the License Agreement provided for a payment by Acuity of up to $75,000 to be used the Institute of Hygiene and Social Medicine, Leopold-Franzens-University of Innsbruck, Austria and or the Phase II clinical investigators to be used to accelerate recruitme